Research & Literature

Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.

Qaddoumi I, Orisme W, Wen J, et al.

Acta neuropathologica 2016; (131(6)):833-45 doi:10.1007/s00401-016-1539-z.

Manifestations of Pediatric Intracranial Hypertension From the Intracranial Hypertension Registry.

Aylward SC, Waslo CS, Au JN, Tanne E

Pediatric neurology 2016; (61()):76-82.

Rapid malignant transformation of low-grade astrocytoma in a pregnant woman.

Hanada T, Rahayu TU, Yamahata H, et al.

The journal of obstetrics and gynaecology research 2016; (42(10)):1385-1389 doi:10.1111/jog.13072.

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Karsy M, Guan J, Cohen AL, et al.

Current neurology and neuroscience reports 2017; (17(2)):19 doi:10.1007/s11910-017-0722-5.

Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits.

Keil VC, Pintea B, Gielen GH, et al.

Journal of neuro-oncology 2017; (133(1)):155-163 doi:10.1007/s11060-017-2424-x.

Adult pilocytic astrocytoma of conus medullaris: clinical considerations and review of the literature.

Lavrador JP, Oliveira E, Pimentel J, Livraghi S

CNS oncology 2017; (6(2)):107-110 doi:10.2217/cns-2016-0030.

Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia.

Rajagopal R, Abd-Ghafar S, Ganesan D, et al.

Journal of global oncology 2017; (3(2)):143-156 doi:10.1200/JGO.2015.002659.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, et al.

Neuro-oncology 2018; (20(1)):123-131 doi:10.1093/neuonc/nox149.

Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence.

Bond KM, Hughes JD, Porter AL, et al.

World neurosurgery 2018; (110()):276-283 doi:10.1016/j.wneu.2017.11.102.

Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis.

Phan K, Ng W, Lu VM, et al.

World neurosurgery 2018; (111()):e539-e545 doi:10.1016/j.wneu.2017.12.112.

Study on cognitive decline in patients diagnosed with brain tumors.

Bondari S, Bondari D, Pîrşcoveanu M, et al.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2017; (58(4)):1185-1192.

Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.

Berntsson SG, Merrell RT, Amirian ES, et al.

Journal of neurology 2018; (265(6)):1432-1442 doi:10.1007/s00415-018-8857-0.

Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer.

Lv Y, Zhang J, Liu Z, et al.

Molecular and clinical oncology 2018; (9(1)):70-74 doi:10.3892/mco.2018.1622.

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting.

Ameratunga M, Miller D, Ng W, et al.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2018; (56()):127-130 doi:10.1016/j.jocn.2018.06.032.

Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

van Dijken BRJ, van Laar PJ, Smits M, et al.

Journal of magnetic resonance imaging : JMRI 2019; (49(1)):11-22 doi:10.1002/jmri.26306.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

Pires da Silva I, Glitza IC, Haydu LE, et al.

Pigment cell & melanoma research 2019; (32(4)):553-563 doi:10.1111/pcmr.12775.

Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.

Dahlrot RH, Larsen P, Boldt HB, et al.

Journal of neuropathology and experimental neurology 2019; (78(7)):633-640 doi:10.1093/jnen/nlz032.

Awake craniotomy: anesthetic considerations based on outcome evidence.

Sewell D, Smith M

Current opinion in anaesthesiology 2019; (32(5)):546-552 doi:10.1097/ACO.0000000000000750.

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.

Nasrallah MP, Binder ZA, Oldridge DA, et al.

Academic pathology 2019; (6()):2374289519848353 doi:10.1177/2374289519848353.

Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.

Patel SH, Bansal AG, Young EB, et al.

AJNR. American journal of neuroradiology 2019; (40(7)):1149-1155 doi:10.3174/ajnr.A6102.

Qualitative study: patients' and parents' views on brain tumour MRIs.

Tyldesley-Marshall N, Greenfield S, Neilson S, et al.

Archives of disease in childhood 2020; (105(2)):166-172 doi:10.1136/archdischild-2019-317306.

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Schreck KC, Grossman SA, Pratilas CA

Cancers 2019; (11(9)) doi:10.3390/cancers11091262.

Association of Intracranial Pressure and Spontaneous Retinal Venous Pulsation.

D'Antona L, McHugh JA, Ricciardi F, et al.

JAMA neurology 2019; (76(12)):1502-1505 doi:10.1001/jamaneurol.2019.2935.

Primary Spinal Astrocytomas: A Literature Review.

Ogunlade J, Wiginton JG, Elia C, et al.

Cureus 2019; (11(7)):e5247 doi:10.7759/cureus.5247.

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.

Kim YZ, Kim CY, Wee CW, et al.

Brain tumor research and treatment 2019; (7(2)):74-84 doi:10.14791/btrt.2019.7.e43.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

Appay R, Dehais C, Maurage CA, et al.

Neuro-oncology 2019; (21(12)):1519-1528 doi:10.1093/neuonc/noz124.

Feasibility of awake craniotomy in the pediatric population.

Alcaraz García-Tejedor G, Echániz G, Strantzas S, et al.

Paediatric anaesthesia 2020; (30(4)):480-489 doi:10.1111/pan.13833.

High-grade gliomas in adolescents and young adults highlight histomolecular differences from their adult and pediatric counterparts.

Roux A, Pallud J, Saffroy R, et al.

Neuro-oncology 2020; (22(8)):1190-1202 doi:10.1093/neuonc/noaa024.

Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.

Choi J, Kim SH, Ahn SS, et al.

Scientific reports 2020; (10(1)):2086 doi:10.1038/s41598-020-59089-x.

Improvement of the Efficiency and Completeness of Neuro-Oncology Patient Referrals to a Tertiary Center Through the Implementation of an Electronic Referral System: Retrospective Cohort Study.

Fernández-Méndez R, Wong MY, Rastall RJ, et al.

Journal of medical Internet research 2020; (22(3)):e15002 doi:10.2196/15002.

Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.

Alan O, Telli TA, Tuylu TB, et al.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(2)):329-339 doi:10.1177/1078155220920684.

Trametinib-based Treatment of Pediatric CNS Tumors: A Single Institutional Experience.

Paul MR, Pehlivan KC, Milburn M, et al.

Journal of pediatric hematology/oncology 2020; (42(8)):e730-e737 doi:10.1097/MPH.0000000000001819.

A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells.

Usta D, Sigaud R, Buhl JL, et al.

Molecular cancer therapeutics 2020; (19(8)):1736-1750 doi:10.1158/1535-7163.MCT-19-1021.

Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas.

Mirchia K, Richardson TE

Cancers 2020; (12(7)) doi:10.3390/cancers12071817.

Multiple Lesions Accompanied by Postoperative Spontaneous Intracystic Hemorrhage in a Pediatric Patient with Pilocytic Astrocytoma.

Parenrengi MA, Aji YK

Asian journal of neurosurgery 2020; (15(2)):409-413 doi:10.4103/ajns.AJNS_308_19.

A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.

Higa N, Akahane T, Yokoyama S, et al.

Cancer science 2020; (111(10)):3902-3911 doi:10.1111/cas.14597.

Memantine for Prevention of Brain Irradiation-Induced Cognitive Toxicity: A Tale of an Underappreciated and Underused Intervention.

Chilukuri S, Burela N

JCO global oncology 2020; (6()):1384-1388 doi:10.1200/GO.20.00342.

Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas.

Rossi M, Gay L, Ambrogi F, et al.

Neuro-oncology 2021; (23(5)):812-826 doi:10.1093/neuonc/noaa225.

Reappraisal of haemorrhagic suprasellar pilocytic astrocytoma during adulthood.

Cortez GM, Monteiro A, Ludwig B, Hanel R

BMJ case reports 2020; (13(10)) doi:10.1136/bcr-2020-235662.

Early atypical malignant transformation of diffuse low-grade astrocytoma: The importance of genotyping.

Valente Aguiar P, Sousa O, Silva R, et al.

Neurocirugia 2020; doi:10.1016/j.neucir.2020.09.003.

Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas.

Ball MK, Kollmeyer TM, Praska CE, et al.

Neuro-oncology advances 2020; (2(1)):vdaa109 doi:10.1093/noajnl/vdaa109.

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Weller M, van den Bent M, Preusser M, et al.

Nature reviews. Clinical oncology 2021; (18(3)):170-186 doi:10.1038/s41571-020-00447-z.

FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation.

Lohmann P, Elahmadawy MA, Gutsche R, et al.

Cancers 2020; (12(12)) doi:10.3390/cancers12123835.

Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.

Zhang Z, Jin Z, Yang X, et al.

Frontiers in neurology 2020; (11()):591615 doi:10.3389/fneur.2020.591615.

Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.

Lee D, Riestenberg RA, Haskell-Mendoza A, Bloch O

Journal of neuro-oncology 2021; (152(1)):89-98 doi:10.1007/s11060-020-03677-4.

A Novel Intraoperative Brain Mapping Integrated Task-Presentation Platform.

Hameed NUF, Zhao Z, Zhang J, et al.

Operative neurosurgery (Hagerstown, Md.) 2021; (20(5)):477-483 doi:10.1093/ons/opaa476.

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma.

Chai R, Li G, Liu Y, et al.

Cancer biology & medicine 2021; (18(1)):272-282 doi:10.20892/j.issn.2095-3941.2020.0179.

Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.

Werner JM, Weller J, Ceccon G, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(13)):3704-3713 doi:10.1158/1078-0432.CCR-21-0471.

Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members.

Fortin Ensign S, Hrachova M, Chang S, Mrugala MM

Neuro-oncology practice 2021; (8(3)):310-316 doi:10.1093/nop/npab003.

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey.

Schäfer N, Bumes E, Eberle F, et al.

Journal of neuro-oncology 2021; (153(3)):479-485 doi:10.1007/s11060-021-03784-w.

H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Ammendola S, Caldonazzi N, Simbolo M, et al.

Virchows Archiv : an international journal of pathology 2021; (479(5)):987-996 doi:10.1007/s00428-021-03134-1.

Prognostic and Predictive Biomarkers in Gliomas.

Śledzińska P, Bebyn MG, Furtak J, et al.

International journal of molecular sciences 2021; (22(19)) doi:10.3390/ijms221910373.

Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study.

Anand N, Husain N, Varshney R, et al.

Journal of carcinogenesis 2021; (20()):20 doi:10.4103/jcar.jcar_17_21.

Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018.

Lin D, Wang M, Chen Y, et al.

Frontiers in oncology 2021; (11()):748061 doi:10.3389/fonc.2021.748061.

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

Perez A, Huse JT

Current neurology and neuroscience reports 2021; (21(12)):67 doi:10.1007/s11910-021-01153-8.

Stereotactic biopsy for intracranial space occupying lesions: Experience in a referral hospital in Mexico.

Navarro-Olvera JL, Parra-Romero G, Carrillo-Ruiz JD, et al.

Cirugia y cirujanos 2021; (89(6)):763-768 doi:10.24875/CIRU.20001009.

Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma.

Rana R, Chauhan K, Gautam P, et al.

Frontiers in oncology 2021; (11()):778754 doi:10.3389/fonc.2021.778754.

Neuro-oncology and supportive care: the role of the neurologist.

Stec NE, Walbert T

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(2)):939-950 doi:10.1007/s10072-021-05862-3.

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma.

Huang LE

Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020246.

Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.

Sidibe I, Tensaouti F, Roques M, et al.

Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020285.

Advanced Imaging Techniques for Newly Diagnosed and Recurrent Gliomas.

Carrete LR, Young JS, Cha S

Frontiers in neuroscience 2022; (16()):787755 doi:10.3389/fnins.2022.787755.

Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.

Whitfield BT, Huse JT

Brain pathology (Zurich, Switzerland) 2022; (32(4)):e13062 doi:10.1111/bpa.13062.

Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Lam K, Eldred BSC, Kevan B, et al.

Neuro-oncology advances 2022; (4(1)):vdac030 doi:10.1093/noajnl/vdac030.

Association between surgical volume and outcomes after craniotomy for brain tumor removal: A South Korean nationwide cohort study.

Choi HR, Song IA, Oh TK

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022; (100()):75-81 doi:10.1016/j.jocn.2022.04.007.

The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview.

Torp SH, Solheim O, Skjulsvik AJ

Acta neurochirurgica 2022; (164(9)):2453-2464 doi:10.1007/s00701-022-05301-y.

Diffuse leptomeningeal glioneuronal tumor in an 8-year-old girl: case report and review of the literature.

Cambruzzi E, Medeiros MS, Cardoso CE, et al.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023; (39(1)):301-305 doi:10.1007/s00381-022-05625-1.

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.

Fortin Ensign SP, Jenkins RB, Giannini C, et al.

Neuro-oncology 2023; (25(1)):28-36 doi:10.1093/neuonc/noac205.

DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis.

Bernhardt D, König L, Grosu A, et al.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2022; (198(10)):873-883 doi:10.1007/s00066-022-01994-3.

Infiltration in Pilocytic Astrocytoma: A Diagnostic Pitfall.

Alturkustani M

Cureus 2022; (14(8)):e27940 doi:10.7759/cureus.27940.

Prevalence of seizures in brain tumor: A meta-analysis.

Audrey C, Lim KS, Ahmad Zaki R, et al.

Epilepsy research 2022; (187()):107033 doi:10.1016/j.eplepsyres.2022.107033.

Surveillance of long-term complications after treatment of adult brain tumor survivors-review and evidence-based recommendations.

Figuracion KCF, Halasz LM, Lam NY, et al.

Neuro-oncology practice 2022; (9(6)):475-486 doi:10.1093/nop/npac053.

Adult type diffuse gliomas in the new 2021 WHO Classification.

Antonelli M, Poliani PL

Pathologica 2022; (114(6)):397-409 doi:10.32074/1591-951X-823.

Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.

Gianno F, Giovannoni I, Cafferata B, et al.

Pathologica 2022; (114(6)):422-435 doi:10.32074/1591-951X-830.

Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.

Manoharan N, Liu KX, Mueller S, et al.

Neoplasia (New York, N.Y.) 2023; (36()):100857 doi:10.1016/j.neo.2022.100857.

Comparison of the clinical features and treatment outcomes of pilocytic astrocytoma in pediatric and adult patients.

Kim JW, Phi JH, Kim SK, et al.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2023; (39(3)):583-591 doi:10.1007/s00381-023-05839-x.

Molecular pathology and clinical implications of diffuse glioma.

Chai R, Fang S, Pang B, et al.

Chinese medical journal 2022; (135(24)):2914-2925 doi:10.1097/CM9.0000000000002446.

Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.

King AL, Acquaye AA, Mendoza T, et al.

Research square 2023; doi:10.21203/rs.3.rs-2521990/v1.

2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.

Thomas DL

Chinese clinical oncology 2023; (12(1)):7 doi:10.21037/cco-22-120.

Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.

King AL, Acquaye-Mallory AA, Vera E, et al.

BMC cancer 2023; (23(1)):262 doi:10.1186/s12885-023-10671-2.

Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas.

Otani Y, Satomi K, Suruga Y, et al.

Brain tumor pathology 2023; (40(2)):56-65 doi:10.1007/s10014-023-00457-6.

"Scanxiety" and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up - a qualitative study.

Seibel K, Sauer B, Wagner B, Becker G

BMC psychology 2023; (11(1)):119 doi:10.1186/s40359-023-01151-0.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al.

The New England journal of medicine 2023; (389(7)):589-601 doi:10.1056/NEJMoa2304194.

A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.

Tran S, Thomas A, Aliouat I, et al.

Neuropathology and applied neurobiology 2023; (49(4)):e12928 doi:10.1111/nan.12928.

Tumor size, treatment patterns, and survival in neuro-oncology patients before and during the COVID-19 pandemic.

Karamani L, McLean AL, Kamp MA, et al.

Neurosurgical review 2023; (46(1)):226 doi:10.1007/s10143-023-02132-y.

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning.

Kim GJ, Lee T, Ahn S, et al.

NPJ precision oncology 2023; (7(1)):94 doi:10.1038/s41698-023-00450-4.

Epileptic versus neuro-oncological focus of management in pediatric patients with concurrent primary brain lesion and seizures: a systematic review.

Gruber MD, Pindrik J, Damante M, et al.

Journal of neurosurgery. Pediatrics 2023; (32(5)):576-583 doi:10.3171/2023.6.PEDS22440.

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.

Rautajoki KJ, Jaatinen S, Hartewig A, et al.

Acta neuropathologica communications 2023; (11(1)):176 doi:10.1186/s40478-023-01669-9.

Whole brain radiation therapy resulting in radionecrosis: a possible link with radiosensitising chemoimmunotherapy.

Ngu S, Werner C, D' Amico RS, Wernicke AG

BMJ case reports 2023; (16(11)) doi:10.1136/bcr-2023-256758.

Research progress on ferroptosis in gliomas (Review).

Bo Y, Mu L, Yang Z, et al.

Oncology letters 2024; (27(1)):36 doi:10.3892/ol.2023.14169.

A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.

Xi S, Huang Q, Zeng J

Journal of neuropathology and experimental neurology 2024; (83(2)):125-130 doi:10.1093/jnen/nlad112.

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.

Weller M, Felsberg J, Hentschel B, et al.

Acta neuropathologica 2024; (147(1)):11 doi:10.1007/s00401-023-02662-1.

World Health Organization (WHO) Grade 1 Astrocytoma in a Female From Rural India: A Case Report.

Siddiqui MIA, Parihar P, Mishra GV, et al.

Cureus 2023; (15(12)):e50554 doi:10.7759/cureus.50554.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

The Prognostic Role of Volumetric MRI Evaluation in the Surgical Treatment of Glioblastoma.

Aiudi D, Iacoangeli A, Dobran M, et al.

Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030849.

Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.

Sim Y, Choi SH, Lee N, et al.

European journal of radiology 2024; (173()):111384 doi:10.1016/j.ejrad.2024.111384.

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

van den Bent MJ, French PJ, Brat D, et al.

Neuro-oncology 2024; (26(10)):1805-1822 doi:10.1093/neuonc/noae107.

Pediatric-type diffuse low-grade gliomas.

Biswas A, Rao HR, Wagner MW

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(10)):3003-3006 doi:10.1007/s00381-024-06500-x.

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.

Kinslow CJ, Roy S, Iwamoto FM, et al.

Neuro-oncology 2024; (26(10)):1839-1849 doi:10.1093/neuonc/noae102.

Treatment of IDH-mutant glioma in the INDIGO era.

Lin MD, Tsai AC, Abdullah KG, et al.

NPJ precision oncology 2024; (8(1)):149 doi:10.1038/s41698-024-00646-2.

MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.

Zhang J, Qiu X, Feng J, Liu Y

Chinese neurosurgical journal 2024; (10(1)):24 doi:10.1186/s41016-024-00375-2.

Pleomorphic xanthoastrocytoma with NTRK fusion presenting as spontaneous intracranial hemorrhage-case report and literature review.

Wu Y, Aw SJ, Jain S, et al.

Frontiers in pediatrics 2024; (12()):1378608 doi:10.3389/fped.2024.1378608.

Central nervous system pediatric multi-disciplinary tumor board: a single center experience.

Russo R, Verdolotti T, Perna A, et al.

BMC cancer 2024; (24(1)):1146 doi:10.1186/s12885-024-12882-7.

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.

Nakhate V, Lasica AB, Wen PY

Current neurology and neuroscience reports 2024; (24(12)):631-643 doi:10.1007/s11910-024-01378-3.

Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.

Wetzel EA, Nohman AI, Hsieh AL, et al.

Journal of neuro-oncology 2025; (171(2)):373-381 doi:10.1007/s11060-024-04852-7.

Study of Molecular Markers in Glioma and Their Association with Clinicopathological Features.

Singh A, Singh A, Jaiswal AK, et al.

Annals of African medicine 2025; (24(1)):28-36 doi:10.4103/aam.aam_127_23.

Implications of molecular classifications in glioma surgery.

Kalluri AL, Lee JH, Lucas CG, et al.

Journal of neuro-oncology 2025; (171(3)):559-569 doi:10.1007/s11060-024-04883-0.

Role of memantine to mitigate radiation-induced cognitive dysfunction in brain metastasis patient receiving whole brain radiotherapy: a systematic review.

Oktavianda YD, Permata TBM

Radiation oncology journal 2024; (42(4)):281-294 doi:10.3857/roj.2024.00269.

The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia.

Stone TJ, Pickles JC, Ogunbiyi O, et al.

Acta neuropathologica communications 2025; (13(1)):30 doi:10.1186/s40478-024-01922-9.

Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.

Falcão L, Cerqueira GA, Gonçalves JPF, et al.

Neurosurgical review 2025; (48(1)):281.

Clinical Impact of a Next-Generation Sequencing Approach for Glioblastoma Patients.

Vivancos Sánchez C, Esteban Rodríguez MI, Peláez García A, et al.

Cancers 2025; (17(5)) doi:10.3390/cancers17050744.

Efficacy of Hippocampal Avoidance Whole Brain Radiotherapy to Preserve the Cognitive Functions among Brain Metastasis Patients: Systematic Review and Meta-analysis.

Surendran HP, Sah SK, Veeralakshmanan P, et al.

Neurology India 2025; (73(3)):429-445 doi:10.4103/neurol-india.Neurol-India-D-24-00727.

Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact.

Shatara M, Brossier NM, Cluster A, et al.

International journal of clinical oncology 2025; (30(8)):1659-1669 doi:10.1007/s10147-025-02793-3.

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.

Li H, Wu Y, Chen Y, et al.

Acta neuropathologica communications 2025; (13(1)):126 doi:10.1186/s40478-025-02046-4.

Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors.

Rudà R, Bruno F, Pellerino A, et al.

Expert opinion on pharmacotherapy 2025; (26(10)):1163-1175 doi:10.1080/14656566.2025.2516617.

The malignant transformation of an atypical angiocentric glioma, MYB-altered.

Aboubakr O, Wefers AK, Dangouloff-Ros V, et al.

Acta neuropathologica communications 2025; (13(1)):161 doi:10.1186/s40478-025-02070-4.

Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.

Kurokawa R, Hagiwara A, Ueda D, et al.

La Radiologia medica 2025; (130(11)):1871-1887 doi:10.1007/s11547-025-02078-9.

Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).

Encarnación JA, Manso C, Royo-Villanova M, et al.

Medical sciences (Basel, Switzerland) 2025; (13(4)) doi:10.3390/medsci13040233.

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

Cloughesy TF, van den Bent MJ, Touat M, et al.

The Lancet. Oncology 2025; (26(12)):1665-1675 doi:10.1016/S1470-2045(25)00472-3.

Pediatric-Type Diffuse Low Grade Glioma.

Kotch C, Green K, Fisher MJ, Hargrave D

Advances in cancer research 2025; (167()):1-35 doi:10.1016/bs.acr.2025.08.006.

New and Emerging Therapies for Patients with Low-Grade Glioma.

Peters KB

CNS drugs 2026; (40(1)):1-18 doi:10.1007/s40263-025-01238-9.

Advances in the management of patients with IDH-mutant glioma.

Rossi J, Picca A, Santonocito OS, et al.

The oncologist 2025; (30(12)) doi:10.1093/oncolo/oyaf391.

Exploring Demographic, Clinical, Surgical, and Imaging Features in Relation to CDKN2A/B Status in Meningiomas.

Abofani H, Ben-Moyal O, Cohen ZR, et al.

World neurosurgery 2026; (205()):124699 doi:10.1016/j.wneu.2025.124699.

Unpredictable Evolution of Pilocytic Astrocytoma in Adults: A Case Series and Diagnostic Challenges.

Sincu A, Orasanu CI, Voda RI, et al.

The American journal of case reports 2025; (26()):e947774 doi:10.12659/AJCR.947774.

AI-Powered Histology for Molecular Profiling in Brain Tumors: Toward Smart Diagnostics from Tissue.

Sakaguchi M, Yoshizawa A, Masui K, et al.

Cancers 2025; (18(1)) doi:10.3390/cancers18010009.